A carregar...
Harnessing soft tissue sarcoma with low-dose pazopanib – a matter of blood levels
BACKGROUND: Pazopanib is a tyrosine kinase inhibitor indicated for the treatment of renal cell carcinoma and soft tissue sarcoma. Despite the high inter-patient variability in pharmacokinetic exposure, pazopanib is administered at a fixed dose of 800 mg once daily (QD). Pharmacokinetic exposure is l...
Na minha lista:
| Publicado no: | BMC Cancer |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6276240/ https://ncbi.nlm.nih.gov/pubmed/30509247 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-5043-9 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|